

ABSTRACT

Compositions and methods for eliciting an *in vivo* cytotoxic lymphocyte (CTL) response against a modified soluble protein antigen are disclosed. The modified soluble protein antigen comprises an added peptidic sequence which facilitates entry of the modified antigen into antigen presenting cells (APC).

604727-48973450